Long-term Investigation of Resveratrol on Fat Metabolism in Obese Men With Nonalcoholic Fatty Liver Disease
Long-term Investigation of Resveratrol on Fat Metabolism in Obese Men With Nonalcoholic Fatty Liver Disease
The purpose of this study is to investigate potential metabolic effects of resveratrol in
 obese healthy men with non-alcoholic fatty liver disease.

 The investigators hypothesize that resveratrol will:

 -  decrease hepatic very-low-density-lipoprotein-triglyceride (VLDL-TG) secretion

 -  decrease liver fat content

 -  increase insulin sensitivity

 The investigators will look at changes in:

 -  lipid turnover (VLDL-TG kinetics, palmitate kinetics, indirect calorimetry)

 -  liver fat content (MR liver spectroscopy)

 -  insulin sensitivity (glucose kinetics during hyperinsulinaemic euglycaemic clamp)

 -  body composition (DXA and MRI)

 -  lipase activity and fat cell size (fat biopsy from abdominal and femoral adipose tissue)
Inclusion Criteria:

 -  Male

 -  25-65 years

 -  Obesity (BMI > 28 kg/m2, waist/hip ratio > 0,95)

 -  Have nonalcoholic fatty liver disease (NAFLD)(intervention group) or do not have NAFLD
 (control group)

 -  May have hypertension and/or hypercholesterolemia

 -  Written informed consent

 Exclusion Criteria:

 -  Any other disease than NAFLD (e.g. diabetes, thyroid or parathyroid disease, heart,
 liver or kidney disease)

 -  Present and previous malignancy

 -  Alcohol dependency (more than 21 units of alcohol per week)

 -  History of smoking

 -  Participation in studies with radioactive isotopes within the last six months

 -  Hemoglobin under normal range regarding to sex (under 8.3 mmol/l for men)